Fund moves
16.2%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Nov 2, 2026 · Notice filed Nov 2, 2026
An Orchestra Biomed officer told the SEC about a plan to sell $89K of Orchestra Biomed shares around Nov 2, 2026. The filing says the shares were acquired as compensation. That is a tiny part of all Orchestra Biomed shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Insider buying
5 insiders in a week, a first since 2020Traded Nov 9 · filed 3 days later
A major shareholder of Orchestra Biomed paid $6M out of pocket for Orchestra Biomed shares. 4 other people at Orchestra Biomed bought some too, in the same month. It was the first purchase in 19 months.
Insider buying
5 insiders in a week, a first since 2020Traded Nov 9 · filed the same day
The CFO of Orchestra Biomed paid $5K out of pocket for Orchestra Biomed shares. 4 other people at Orchestra Biomed bought some too, in the same month. It was the first purchase in 15 months.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.